MESSAGE (ENGLISH VERSION)
<head>
</head>
<body>
<p class=”MsoNormal” align=”justify” style=”margin-bottom: 6.0pt; line-height: 115%”>
<b><span lang=”EN-US” style=”line-height: 115%”><font size=”11.0pt” face=”Arial Narrow,sans-serif”>Admission
and conditional introduction of the Company’s series J shares to trading
on the main market of the WSE. Setting the date of the first listing of
the Company’s series J shares after their assimilation with shares
traded on the main market.</font></span></b>
</p>
<p class=”MsoNormal” align=”justify” style=”margin-bottom: 6.0pt; line-height: 115%”>
<b><span lang=”EN-US” style=”line-height: 115%”><font size=”11.0pt” face=”Arial Narrow,sans-serif”>Current
Report No.: 19/2024</font></span></b>
</p>
<p class=”MsoNormal” align=”justify” style=”margin-bottom: 6.0pt; line-height: 115%”>
<b><span lang=”EN-US” style=”line-height: 115%”><font size=”11.0pt” face=”Arial Narrow,sans-serif”>Date:
September 13, 2024</font></span></b>
</p>
<p class=”MsoNormal” align=”justify” style=”margin-bottom: 6.0pt; line-height: 115%”>
<b><span lang=”EN-US” style=”line-height: 115%”><font size=”11.0pt” face=”Arial Narrow,sans-serif”>Legal
Basis: Article 56(1)(2) of the Act on Public Offering – Current and
Periodic Information<o p=”#DEFAULT” style=”line-height: 115%”></font></span></b>
</p>
<p class=”MsoNormal” align=”justify” style=”margin-bottom: 6.0pt; line-height: 115%”>
<span lang=”EN-US” style=”line-height: 115%”><font size=”11.0pt” face=”Arial Narrow,sans-serif”>The
Management Board of Medicalgorithmics S.A. with its registered office in
Warsaw (the “<b>Issuer</b>”, the “<b>Company</b>”),
hereby announces that on 13 September 2024 it received information on
the adoption of Resolution No. 1134/2024 of the Management Board of the
Warsaw Stock Exchange S.A. (“<b>WSE</b>”) on the admission and
introduction to exchange trading on the WSE Main Market of series J
bearer ordinary shares of Medicalgorithmics S.A. (the “<b>Resolution</b>”).</font></span>
</p>
<p class=”MsoNormal” align=”justify” style=”margin-bottom: 6.0pt; line-height: 115%”>
<span lang=”EN-US” style=”line-height: 115%”><font size=”11.0pt” face=”Arial Narrow,sans-serif”>Pursuant
to the Resolution, </font></span><font size=”11.0pt” face=”Arial Narrow,sans-serif”><span>1,194,331
(one million one hundred and ninety-</span><span lang=”EN-US” style=”line-height: 115%”>four
thousand three hundred and thirty-one) series J bearer common shares of
the Company carrying ISIN code </span><span>PLMDCLG00056</span><span lang=”EN-US” style=”line-height: 115%”>
(the “<b>Shares</b>”), with a nominal value of 0.10 (ten groszy)
each, were admitted to trading on the main market. </span></font>
</p>
<p class=”MsoNormal” align=”justify” style=”margin-bottom: 6.0pt; line-height: 115%”>
<span lang=”EN-US” style=”line-height: 115%”><font size=”11.0pt” face=”Arial Narrow,sans-serif”>Pursuant
to the Resolution, the Shares will be listed on the main market as of
September 20, 2024, subject to the assimilation of the Shares by the
National Securities Depository (Krajowy Depozyt Papierów Wartościowych
S.A.) on September 20, 2024, with the Company’s shares traded on the
stock exchange, under the code PLMDCLG00015. The Company will announce
the assimilation of the Shares in a separate current report.</font></span>
</p>
<p class=”MsoNormal” align=”justify” style=”margin-bottom: 6.0pt; line-height: 115%”>
<span lang=”EN-US” style=”line-height: 115%”><font size=”11.0pt” face=”Arial Narrow,sans-serif”>The
Company reminds that the Shares were issued in accordance with the
Resolution No. 4 of the Company’s Extraordinary General Meeting of
October 28, 2022 Increase of the Company’s share capital through issue
of series I, J, K and L shares; waiver of existing shareholders’
subscription rights; private subscription offer for a designated entity;
and change of Article 5 (1) and (2) of the Articles of Association. The
shares were registered with the National Securities Depository on March
7, 2023, as the Company announced in current report number 8/2023 on
March 8, 2023.</font></span>
</p>
<p class=”MsoNormal” align=”justify” style=”margin-bottom: 6.0pt; line-height: 115%”>
<span lang=”EN-US” style=”line-height: 115%”><font size=”11.0pt” face=”Arial Narrow,sans-serif”>The
Company reminds that in the current report No. 55/2022 it informed on
October 1, 2022, that 4,976,384 Shares were acquired by Biofund Capital
Management LLC with its registered office in Miami (USA). These shares
are to be introduced to trading under the applicable exceptions to the
obligation to prepare an issue prospectus, and the planned date of
introducing all these shares to trading has been set at the end of 2026.</font></span>
</p>
</body>
</html>
Zgłoś naruszenie/Błąd
Oryginalne źródło ZOBACZ
Dodaj kanał RSS
Musisz być zalogowanym aby zaproponować nowy kanal RSS